| Objective1.To study the clinical efficacy of Jiawei Guizhi Fulling Pill before and after treatment in patients with acute exacerbation of chronic obstructive pulmonary disease（COPD）（syndrome of stasis of pulmonary arteries）by randomized controlled trial,and to provide an effective and safe treatment plan for the disease.2.Through this study,to clarify the efficacy and safety of Jiawei Guizhi Fuling pill for the acute exacerbation of copd pulmonary artery stasis syndrome,and provide a new clinical treatment thinking for the treatment of this disease.Methods1.A total of 80 patients with AECOPD（pulmonary artery stasis syndrome）admitted to the inpatient Department of Taizhou Hospital of Traditional Chinese Medicine from December 2020 to September 2021 were selected and divided into treatment group and control group by random number table method.2.On the basis of health education and smoking cessation education,the control group was given standardized treatment of Western medicine（oxygen therapy,anti-infection,antitussive and phlegm,spasmolysis and antiasthmatic therapy recommended by guidelines）,while the treatment group was treated with flavored Jiawei Guizhi Fuling pill.3.A 10-day treatment cycle was used to observe inflammatory indicators（WBC,CRP）,coagulation function（D-dimer,fibrinogen）,pulmonary artery pressure,recurrence rate within 3 months,TCM symptom score（wheezing,cough,expectoration,epigastrium,chills in extremities）and other factors before and after treatment in both groups.4.Use SPSS25.0 statistical software to analyze the collected data.Results1.TCM symptom score:the experimental group and the control group achieved significant clinical efficacy in five TCM symptom scores（P<0.05）,and the experimental group was superior to the control group in terms of effective rate.2.Inflammatory indexes:the treatment group and the control group achieved clinical curative effect,with statistical significance（P<0.05）.The results between the two groups were better than those in the treatment group（P<0.05）.3.Coagulation function:the treatment group achieved better efficacy,with statistical significance（P<0.05）;In the control group,there was no statistically significant improvement（P>0.05）.4.Pulmonary arterial pressure:The control group showed no improvement in reducing pulmonary hypertension,and the treatment group improved numerically,but not statistically significant（P>0.05）.5.Recurrence rate within three months:both the treatment group and the control group benefited numerically,and the difference between the two groups was statistically significant（P<0.05）.ConclusionThe data analysis shows that Jiawei Guizhi Fuling pill can improve the coagulation function and have a certain effect on hemodynamics.To a certain extent,it can reduce pulmonary hypertension,delay the process of pulmonary heart disease and reduce the risk of related complications.Besides,it can effectively reduce the risk and frequency of acute exacerbation of patients,the risk of lung function deterioration and the economic burden of patients.It can also improve a series of symptoms caused by cold,phlegm and blood stasis.In conclusion,Jiawei Guizhi Fuling Pill has definite clinical efficacy and is safe and reliable for patients with AECOPD. |
PDF Full Text Request